Digital Screening for Cognitive Impairment

For the Early Detection of Dementia

On June 8, 2021, the U.S. Food and Drug Administration granted expedited approval to Aducanumab to treat Alzheimer's disease (AD) as the only drug that acts on the pathology of AD by reducing amyloid-β, which is believed to be the etiologic agent of AD. Aducanumab, developed by Biogen and Eisai, has been shown to reduce amyloid-β in studies of patients with mild cognitive impairment (MCI) or mild dementia, the early stages of AD. However, the actual effect on cognitive impairment has only been confirmed by post-hoc analysis, with conflicting results in two phase III trials.

Some have criticized the need to show how much of a clinically meaningful difference, recently described as a Minimal Clinically Important Difference, with the use of Aducanumab. Nevertheless, the fact remains that it has the potential to lead to the fundamental treatment of AD. It is easy to imagine that early detection of cognitive impairment, especially the identification of MCI before dementia becomes apparent, will become increasingly essential in the future.

(Continue to the next)

The information contained in this article is compiled by the respective authors based on publicly available information. We assume no responsibility whatsoever for any damage or disadvantage caused by actions taken based on such information. Unauthorized reproduction of articles, photos, charts, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Corporation